Helena Marzo-Ortega

List of Publications by Year
in descending order

159 papers	11,285 citations	53794 45 h-index	30087 103 g-index
159 all docs	159 docs citations	159 times ranked	7693 citing authors

#	Article	IF	Citations
1	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.9	1,220
2	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, 43, 761-767.	21.4	778
3	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, 75, 499-510.	0.9	743
4	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Annals of the Rheumatic Diseases, 2009, 68, 1520-1527.	0.9	719
5	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.9	609
6	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 2012, 71, 4-12.	0.9	405
7	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Annals of the Rheumatic Diseases, 2015, 74, 1327-1339.	0.9	402
8	Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. Arthritis and Rheumatism, 2001, 44, 2112-2117.	6.7	399
9	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2016, 75, 1958-1963.	0.9	383
10	Severity of baseline magnetic resonance imagingâ€“evident sacroiliitis and HLAâ€“B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis and Rheumatism, 2008, 58, 3413-3418.	6.7	323
11	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, The, 2017, 389, 2317-2327.	13.7	316
12	Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Annals of the Rheumatic Diseases, 2004, 63, 382-385.	0.9	313
13	Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines, 2021, 9, 435.	4.4	284
14	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 2013, 72, 986-991.	0.9	240
15	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2016, 75, 1016-1023.	0.9	188
16	The role of biomechanical factors and HLAâ€B27 in magnetic resonance imagingâ€determined bone changes in plantar fascia enthesopathy. Arthritis and Rheumatism, 2002, 46, 489-493.	6.7	182
17	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Journal of Rheumatology, 2016, 43, 1724-1734.	2.0	175
18	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.9	171

#	Article	IF	Citations
19	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Annals of the Rheumatic Diseases, 2015, 74, 830-835.	0.9	161
20	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	12.8	149
21	Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Annals of the Rheumatic Diseases, 2005, 64, 1568-1575.	0.9	143
22	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet, The, 2020, 395, 53-64.	13.7	138
23	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Annals of the Rheumatic Diseases, 2017, 76, 571-592.	0.9	137
24	Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Annals of the Rheumatic Diseases, 2009, 68, 1721-1727.	0.9	134
25	Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. Arthritis and Rheumatology, 2017, 69, 1816-1822.	5.6	121
26	Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis and Rheumatism, 2009, 60, 1331-1341.	6.7	116
27	Evidence that tissue resident human enthesis Î³Î´T-cells can produce IL-17A independently of IL-23R transcript expression. Annals of the Rheumatic Diseases, 2019, 78, 1559-1565.	0.9	109
28	Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Annals of the Rheumatic Diseases, 2003, 62, 74-76.	0.9	100
29	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.9	85
30	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet, The, 2018, 392, 134-144.	13.7	81
31	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care and Research, 2017, 69, 1020-1029.	3.4	79
32	Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care and Research, 2016, 68, 838-844.	3.4	73
33	The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. Frontiers in Immunology, 2018, 9, 2668.	4.8	73
34	Identification of myeloid cells in the human enthesis as the main source of local IL-23 production. Annals of the Rheumatic Diseases, 2019, 78, 929-933.	0.9	70
35	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 1387-1393.	0.9	69
36	Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open, 2017, 3, e000592.	3.8	68

#	Article	IF	Citations
37	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.9	64
38	Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2009, 38, 79-83.	1.1	63
39	Tumour necrosis factor-Î± inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-334.	2.8	62
40	Brief Report: Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease Relates to HLAâ€“B27. Arthritis and Rheumatism, 2013, 65, 2274-2278.	6.7	59
41	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.9	59
42	The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Review of Clinical Immunology, 2019, 15, 123-134.	3.0	54
43	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 778-781.	0.9	53
44	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Annals of the Rheumatic Diseases, 2016, 75, 1034-1042.	0.9	53
45	Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3496-3501.	6.7	49
46	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49
47	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). RMD Open, 2021, 7, e001546.	3.8	46
48	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
49	Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 963-968.	1.9	42
50	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td	1.9	41
51	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Therapeutic Advances in Chronic Disease, 2018, 9, 77-87.	2.5	40
52	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Research and Therapy, 2019, 21, 38.	3.5	38
53	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. Archives of Dermatological Research, 2016, 308, 201-205.	1.9	35
54	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open, 2016, 2, e000311.	3.8	31

#	Article	IF	Citations
55	Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open, 2021, 7, e001888.	3.8	30
56	A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis and Rheumatism, 2007, 57, 154-160.	6.7	28
57	Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study. British Journal of Dermatology, 2007, 156, 1005-1009.	1.5	28
58	Axial Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2020, 46, 327-341.	1.9	23
59	Non-radiographic versus radiographic axSpA: whatâ€™s in a name?. Rheumatology, 2020, 59, iv18-iv24.	1.9	22
60	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. Joint Bone Spine, 2018, 85, 447-453.	1.6	21
61	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. Journal of Rheumatology, 2019, 46, 701-709.	2.0	21
62	The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists. Journal of Rheumatology, 2017, 44, 780-785.	2.0	20
63	Magnetic resonance imaging in spondyloarthritis. Current Opinion in Rheumatology, 2010, 22, 381-387.	4.3	19
64	5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatology, The, 2020, 2, e339-e346.	3.9	19
65	Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27â€“positive Male Subjects. Journal of Rheumatology, 2018, 45, 202-205.	2.0	18
66	The concept of disease modification in spondyloarthropathy. Journal of Rheumatology, 2002, 29, 1583-5.	2.0	18
67	The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 169-180.	2.7	16
68	Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and Therapy, 2019, 6, 435-450.	2.3	16
69	Threeâ€dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. Clinical and Experimental Dermatology, 2019, 44, 462-465.	1.3	16
70	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. Pharmacoeconomics, 2018, 36, 1015-1027.	3.3	15
71	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	5.6	15
72	Michelangelo and Medicine. Journal of the Royal Society of Medicine, 2002, 95, 514-515.	2.0	14

#	Article	IF	Citations
73	The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin. Journal of Rheumatology, 2020, 47, 1026-1030.	2.0	14
74	Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis: TableÂ1. Annals of the Rheumatic Diseases, 2016, 75, 1418-1420.	0.9	13
75	Minocycline induced autoimmune disease in rheumatoid arthritis: a missed diagnosis?. Journal of Rheumatology, 2001, 28, 377-8.	2.0	13
76	Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls. Clinical and Experimental Rheumatology, 2017, 35, 872.	0.8	13
77	Poor awareness of inflammatory back pain and axial spondyloarthritis among secondary care specialists. Clinical Rheumatology, 2016, 35, 2627-2628.	2.2	12
78	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. Clinical and Experimental Rheumatology, 2018, 36, 115-120.	0.8	12
79	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and Therapy, 2021, 8, 273-288.	2.3	11
80	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology, 2021, 60, 5795-5800.	1.9	10
81	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatology and Therapy, 2021, 8, 1775-1787.	2.3	10
82	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 490-495.	0.9	10
83	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. BMC Musculoskeletal Disorders, 2017, 18, 303.	1.9	9
84	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. Rheumatology, 2015, 54, 200-202.	1.9	8
85	Receptor activator of nuclear factor kappa-Î' ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.8	8
86	The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. Clinical Rheumatology, 2022, 41, 3573-3581.	2.2	8
87	MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. RMD Open, 2018, 4, e000599.	3.8	7
88	Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy, 2021, 8, 135-150.	2.3	7
89	A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service. Journal of the American Academy of Dermatology, 2019, 80, 1796-1798.	1.2	6
90	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. Rheumatology and Therapy, 2020, 7, 759-774.	2.3	6

#	Article	IF	Citations
91	Chest pain mimicking pulmonary embolism may be a common presentation of COVIDâ€19 in ambulant patients without other typical features of infection. Journal of Internal Medicine, 2021, 290, 349-358.	6.0	6
92	Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods. Seminars in Arthritis and Rheumatism, 2021, 51, 940-945.	3.4	6
93	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clinical and Experimental Rheumatology, 2019, 37, 566-574.	0.8	6
94	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. Rheumatology, 2021, 60, 3607-3616.	1.9	5
95	Etanercept treatment in resistant spondyloarthropathy: imaging, duration of effect and efficacy on reintroduction. Clinical and Experimental Rheumatology, 2002, 20, S175-7.	0.8	5
96	Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritisâ€"findings from a United Kingdom cohort. Rheumatology Advances in Practice, 2018, 2, rky036.	0.7	4
97	Consenso ASAS en nomenclatura en espaÃ±ol para las espondiloartritis. ReumatologÃa ClÃnica, 2020, 16, 333-338.	0.5	4
98	Axial spondyloarthritis: coming of age. Rheumatology, 2020, 59, iv1-iv5.	1.9	4
99	â€˜Too much of a good thingâ€™: can network meta-analysis guide treatment decision-making in psoriatic arthritis?. Rheumatology, 2021, 60, 3042-3044.	1.9	4
100	British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021. International Journal of STD and AIDS, 2021, 32, 095646242110202.	1.1	4
101	Joint and entheseal inflammation in the knee region in spondyloarthritis - reliability and responsiveness of two OMERACT whole-body MRI scores. Seminars in Arthritis and Rheumatism, 2021, 51, 933-939.	3.4	4
102	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	1.9	4
103	Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1). Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110666.	2.7	4
104	Early Oligoarthritis. Rheumatic Disease Clinics of North America, 2005, 31, 627-639.	1.9	3
105	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. Journal of Clinical Medicine, 2019, 8, 281.	2.4	3
106	Axial spondyloarthritis: time to stop the split 10 years on. Nature Reviews Rheumatology, 2020, 16, 5-6.	8.0	3
107	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naÃ¯ve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.7	3
108	Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52â€‰weeks. BMC Rheumatology, 2021, 5, 50.	1.6	3

#	Article	IF	Citations
109	Correspondence on â€˜No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€˜physician-reported spondylitisâ€™?â€™. Annals of the Rheumatic Diseases, 2023, 82, e185-e185.	0.9	3
110	Acute Unilateral Sacroiliitis Mimicking Infection on Magnetic Resonance Imaging with Response to Nonsteroidal Antiinflammatory Drugs: A Distinct Presentation of Spondyloarthritis?. Journal of Rheumatology, 2018, 45, 1708-1710.	2.0	2
111	Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply. Rheumatology, 2019, 58, 1115-1117.	1.9	2
112	Correspondence on â€˜Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trialâ€™. Annals of the Rheumatic Diseases, 2023, 82, e164-e164.	0.9	2
113	Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. Expert Review of Clinical Immunology, 2021, 17, 1059-1071.	3.0	2
114	Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatology, 2021, 5, 35.	1.6	2
115	Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!. Indian Journal of Rheumatology, 2020, 15, 64.	0.4	2
116	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110514.	2.7	2
117	Comment on: Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. Rheumatology, 2021, 60, e24-e25.	1.9	2
118	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naÃ¯ve early psoriatic arthritis. Rheumatology Advances in Practice, 2021, 5, rkab086.	0.7	2
119	Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1). Rheumatology Advances in Practice, 2021, 5, rkab098.	0.7	2
120	SAT0313â€…The link between enthesitis and arthritis in psoriatic arthritis: A switch to a vascular phenotype at insertions may play a role in arthritis development. Annals of the Rheumatic Diseases, 2013, 71, 578.1-578.	0.9	1
121	OP0128â€…PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. Annals of the Rheumatic Diseases, 2015, 74, 116.3-117.	0.9	1
122	SAT0396â€…Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2). Annals of the Rheumatic Diseases, 2016, 75, 812.2-813.	0.9	1
123	AB0700â€…Baseline Clinical Characteristics of The Leeds Sparro Early Psoriatic Arthritis Cohort: High Disease and Radiographic Involvement Are Seen Early Even in The Presence of Preserved Quality of Life: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1144.1-1144.	0.9	1
124	FRI0646â€…Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. , 2017, , .		1
125	065â€ƒPersonalising care: the use of anti-drug antibodies and drug trough levels is a safe and cost-effective treatment strategy in spondyloarthritis. Rheumatology, 2018, 57, .	1.9	1
126	176â€ƒSecukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. Rheumatology, 2018, 57, .	1.9	1

#	Article	IF	Citations
127	041â€ƒItâ€™s not only about treating inflammation: clinical psychology intervention for rheumatology patients remains an unmet need in daily practice. Rheumatology, 2019, 58, .	1.9	1
128	Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Rheumatology, 2021, 60, 467-470.	1.9	1
129	POS1175â€…ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 868-869.	0.9	1
130	OP0252â€…ARTHRITIS AND ENTHESITIS IN THE HIP AND PELVIS REGION IN SPONDYLOARTHRITIS â€“ VALIDATION OF TWO WHOLE-BODY MRI METHODS. Annals of the Rheumatic Diseases, 2021, 80, 153.2-154.	0.9	1
131	FRI0286â€…IXEKIZUMAB TREATMENT IMPROVES FATIGUE, SPINAL PAIN, STIFFNESS, AND SLEEP IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 731-732.	0.9	1
132	Receptor activator of nuclear factor kappa-Î’ ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.8	1
133	OA35â€ƒEfficacy of secukinumab and HLA-B27 subtypes: results from a Phase 3b randomised controlled trial in axial SpA. Rheumatology, 2022, 61, .	1.9	1
134	SAT0355â€…Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 721.3-722.	0.9	0
135	FRI0152â€…Decreased Employment, Work Productivity, and Presenteeism in Patients with Ankylosing Spondylitis is Associated with Increased Disease Activity as Measured by Basdai: Table 1.. Annals of the Rheumatic Diseases, 2014, 73, 437.2-437.	0.9	0
136	A2.16 â€…Association of 20 interferon related gene expression with response to infliximab treatment in ankylosing spondylitis: Pilot data. Annals of the Rheumatic Diseases, 2016, 75, A21.2-A22.	0.9	0
137	02.18â€…Can rankl serum levels predict future progression to rheumatoid arthritis in early arthritis clinic patients?. , 2017, , .		0
138	114.â€ƒSECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2). Rheumatology, 2017, 56, .	1.9	0
139	O03â€ƒEfficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results. Rheumatology, 2018, 57, .	1.9	0
140	P23â€ƒImproving the health and wellbeing of young people with inflammatory musculoskeletal disease: implementation of a young persons keyworker within the Leeds rheumatology service. Rheumatology, 2018, 57, .	1.9	0
141	174â€ƒSecukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials. Rheumatology, 2018, 57, .	1.9	0
142	172â€ƒSecukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. Rheumatology, 2018, 57, .	1.9	0
143	246â€ƒSafety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study. Rheumatology, 2019, 58, .	1.9	0
144	253â€ƒPerformance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. Rheumatology, 2019, 58, .	1.9	0

#	Article	IF	Citations
145	FRI0429â€…NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAÃ¯VE, SYSTEMIC) Tj ETQq1 1 0.784314		0
146	BRITSpA at five. Rheumatology, 2020, 59, 699-701.	1.9	0
147	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice, 2020, 4, rkaa043.	0.7	0
148	P83â€ƒIImproving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Rheumatology, 2020, 59, .	1.9	0
149	AB0675â€…COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1369-1370.	0.9	0
150	AB0676â€…FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1370-1371.	0.9	0
151	OP0149â€…RELIABILITY AND RESPONSIVENESS OF TWO OMERACT WHOLE-BODY MRI SCORES OF ENTHESEAL AND JOINT INFLAMMATION IN THE KNEE REGION IN SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 89-90.	0.9	0
152	AB0677â€…GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1371-1372.	0.9	0
153	POS1213â€…IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 889.2-890.	0.9	0
154	Subjective loss of clinical response to TNFi in axSpA relates to recurrence of MRI bone marrow oedema particularly with long-acting agents. Rheumatology, 2021, , .	1.9	0
155	AB0846â€…Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis. , 2018, , .		0
156	The changing face of psoriatic arthritis. Lancet Rheumatology, The, 2022, 4, e313-e315.	3.9	0
157	Dr Andrew Charles Scott Keat, MBBS MD FRCP (1949-2022). Rheumatology, 0, , .	1.9	0
158	Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1). Clinical and Experimental Rheumatology, 0, , .	0.8	0
159	Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1).. Clinical and Experimental Rheumatology, 2022, , .	0.8	0